is dry mouth a side effect of semaglutide GLP-1 Medications and Mouth: Managing New Effects Ozempic & Oral Health! Potential

Recurrent associations between dysbiotic microbial patterns and poor metabolic response further support the hypothesis that gut microbiota may contribute to interindividual differences in response to incretin-based therapies, although definitive mechanistic evidence in humans remains limited (136), and causality between specific microbial taxa, functional pathways, and GLP-1 RA responsiveness cannot be inferred

Requirements typically include BMI 30 (or 27 with comorbidity) and documentation of lifestyle interventions

The acquired data was presented as the arithmetic mean standard error of six observational numbers [41]

& Rose, N.R

In SURMOUNT-5, published in the New England Journal of Medicine in 2025, tirzepatide produced 20.2% average loss versus 13.7% for semaglutide over 72 weeks, a 47% greater relative loss

Honestly, the jury is still out, and robust human clinical trials are lacking